Bristol Myers Squibb vs Pfizer
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Bristol Myers Squibb and Pfizer side by side, using each one’s latest annual report. Here is what stands out:
- Pfizer is the larger business, with $62.6B of revenue in fiscal 2025 against $48.2B for Bristol Myers Squibb.
- Bristol Myers Squibb grew revenue faster (−0.2%, against −1.7%).
- Bristol Myers Squibb turned more of its sales into free cash flow (26.7% FCF margin, against 14.5%).
- Bristol Myers Squibb earned a higher return on the capital invested in it (15.2%, against 7.3%).
- Investors pay more for each dollar of Pfizer’s earnings: a P/E of 39.2x against 13.6x for Bristol Myers Squibb.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Bristol Myers Squibb
BMY
7/10
Revenue growthNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDA
Pfizer
PFE
3/10
5-year growthGross marginShare count change
Side by side
Best in the row
| Latest fiscal year | BMY FY25 | PFE FY25 |
|---|---|---|
| Size | ||
| Market cap | $126.2B | $169.8B |
| Revenue | $48.2B | $62.6B |
| Free cash flow | $12.8B | $9.1B |
| Net income | $7.1B | $7.8B |
| Growth | ||
| Revenue growth | −0.2% | −1.7% |
| 5-year growth | 2.5% | 8.5% |
| Share count change | 0.6% | 0.2% |
| Profitability | ||
| Gross margin | 71.1% | 74.3% |
| Operating margin | — | — |
| Net margin | 14.6% | 12.4% |
| FCF margin | 26.7% | 14.5% |
| Return on capital | 15.2% | 7.3% |
| Return on equity | 40.5% | 8.9% |
| Balance sheet | ||
| Net debt | $36.4B | $54.3B |
| Net debt / EBITDA | 2.4x | 3.2x |
| Dividends and buybacks | $5.0B | $9.8B |
| Valuation & quality | ||
| P/E | 13.6x | 39.2x |
| Piotroski F-score | 8 | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.